Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised …

T Kishimoto, K Hagi, S Kurokawa, JM Kane… - The Lancet …, 2021 - thelancet.com
Background Evidence of comparative benefits of long-acting injectable antipsychotics (LAIs)
versus oral antipsychotics for schizophrenia has been inconsistent across study designs …

Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia

JM Kane, JP McEvoy, CU Correll, PM Llorca - CNS drugs, 2021 - Springer
Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …

Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders

L Boyer, B Falissard, P Nuss, C Collin, S Duret… - Molecular …, 2023 - nature.com
This mirror-image study aimed to evaluate the real-life effectiveness of long-acting injectable
antipsychotics (LAI) in schizophrenia. Patients with schizophrenia initiating LAIs January …

Relapse rates with paliperidone palmitate in adult patients with schizophrenia: results for the 6-month formulation from an open-label extension study compared to real …

I Turkoz, M Daskiran, U Siddiqui… - International Journal …, 2024 - academic.oup.com
Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic
formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have …

Long-acting injectable antipsychotic treatment for schizophrenia in Asian population: a sco** review

N Ma, L Zhang, W Zhang, Y He, C Ye… - … Disease and Treatment, 2023 - Taylor & Francis
Evidence of comparative benefits of long-acting injectable (LAI) antipsychotics in Asian
patients with schizophrenia has been inconsistent. This sco** review aimed to synthesize …

The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review …

CTC Okoli, A Kappi, T Wang… - … Journal of Mental …, 2022 - Wiley Online Library
Long‐acting injectable (LAI) antipsychotic medications may be an important modality of
reducing costs, improving symptoms, and fostering quality of life outcomes for those with …

Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable …

A Vita, A Fagiolini, G Maina, C Mencacci… - Annals of General …, 2023 - Springer
Definition of an appropriate and personalized treatment plan focused on long-term
outcomes is crucial in the management of schizophrenia. Following review of the literature, a …

Unveiling the actual cost of Schizophrenia: An Activity‐Based Costing (ABC) approach

V Latorre, A Messeni Petruzzelli, AE Uva… - … Journal of Health …, 2022 - Wiley Online Library
Background Despite its relatively low lifetime prevalence, the health, social, and economic
burden of Schizophrenia is very significant. In the last 10 years, several studies have …

Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study

C Montemagni, E Del Favero… - Therapeutic …, 2022 - journals.sagepub.com
Background: Partial adherence to antipsychotics is the most common cause of relapses and
rehospitalization in patients with schizophrenia (SZ), leading to higher health care costs and …

Effect of long-acting antipsychotic treatment on psychiatric hospitalization rate in early psychosis patients: a naturalistic study

R Sancho-Echeverria, C Aymerich… - Therapeutic …, 2024 - journals.sagepub.com
Background: The effectiveness of long-acting injectable (LAI) antipsychotics in preventing
relapses of first-episode psychosis is currently debated. Objectives: The study aimed to …